RAPP

Rapport Therapeutics

29.64 USD
+0.96
3.35%
At close Updated Dec 18, 4:00 PM EST
Pre-market
After hours
29.64
0.00
0%
1 day
3.35%
5 days
2.85%
1 month
17.06%
3 months
8.37%
6 months
168.72%
Year to date
61.17%
1 year
57.41%
5 years
42.5%
10 years
42.5%
 

About: Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Employees: 69

0
Funds holding %
of 7,524 funds
0
Analysts bullish %
of 3 analysts
0
Positive news %
of 5 articles
Price charts implemented using Lightweight Charts™